5-(3',4'-Dihydroxyphenyl)-γ-valerolactone
Based on 1 Customer Validation
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone is an intestinal microbiota metabolite of (-)-Epicatechin (HY-N0001). 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone downregulates TNF-α-stimulated phosphorylation of IKK and IκBα, inhibits the transcriptional activation of NF-κB, and suppresses the expression of adhesion molecules and chemokines. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone promotes autophagy, alleviates oxidative stress, maintains osteoblast differentiation, induces G1 phase arrest, inhibits adipogenesis, and scavenges ABTS free radicals. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone inhibits the adhesion of uropathogenic Escherichia coli to bladder epithelial cells; when used in combination with Curcumin (HY-N0005), it downregulates the NLRP3 and NOX2/Nrf2 signaling pathways, thereby reducing microglial activation. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone can be used in research related to diabetes, atherosclerosis, osteoporosis, obesity, neurodegenerative diseases involving microglial activation, and urinary tract infections.
For research use only. We do not sell to patients.
- Purity : 99.16%
- CAS No.: 21618-92-8
- Formula: C11H12O4
- Molecular Weight:208.21
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
|
IKK |
TNF-α |
IκBα |
NF-κB |
ABTS |
NLRP3 |
Nrf2 |
NOX2 |
In Vitro
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (VL) (1.5-50 µM; 6-48 h) shows no cytotoxic effects on LS174T, HepG2, Caco2, or Wt-MDCK cells[1].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (50 µM; 120 min) is rapidly converted to its sulfate conjugate (VLS) in Caco2 and Wt-MDCK cell monolayers; VLS exhibits high apparent permeability in both models, with efflux transporter involvement indicated by an efflux ratio >2 in Caco2 cells[1].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (1.5-50 µM; 90 min for inhibition assays; 2.5-10 µM; 48 h for induction assays), as its sulfate conjugate VLS, mildly activates the BCRP efflux transporter in differentiated Caco2 cells at concentrations of 12.5 to 50 µM, but does not modulate P-gp activity at tested concentrations[1].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (10 µM; up to 120 min) is rapidly metabolized via phase II glucuronidation in human liver S9 fraction (t1/2 = 8.72 min) and more slowly via phase I metabolism in human liver microsomes (t1/2 = 23.08 min), forming two glucuronide conjugates as primary hepatic metabolites[1].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (DHPV) (5-100 μM; 36 h) promotes proliferation of MC3T3-E1 preosteoblast cells and attenuates H2O2-induced cytotoxicity in MC3T3-E1 cells when used at 5-15 μM for 36 h pretreatment followed by 48 h H2O2 exposure[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; 36 h pretreatment, followed by 48 h H2O2 exposure, then up to 14 days in differentiation medium) attenuates H2O2-induced inhibition of osteogenic differentiation in MC3T3-E1 preosteoblast cells, restoring ALP and Runx2 expression, ALP activity, and mineralization capacity[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; 36 h pretreatment, followed by 48 h H2O2 exposure) protects MC3T3-E1 preosteoblast cells from H2O2-induced mitochondrial membrane potential loss, with 15 μM exerting a significant restorative effect[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; 36 h pretreatment, followed by 48 h H2O2 exposure) alleviates H2O2-induced oxidative stress in MC3T3-E1 preosteoblast cells, reducing ROS and MDA levels and restoring SOD activity, with 15 μM exerting significant effects across all measured parameters[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; 36 h pretreatment, followed by 48 h H2O2 exposure) enhances autophagy in H2O2-treated MC3T3-E1 preosteoblast cells via increased LC3-II/I and Beclin-1 expression, with 15 μM exerting a more potent effect[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (15 μM; 36 h pretreatment, followed by 48 h H2O2 exposure) upregulates SIRT1 protein expression in MC3T3-E1 preosteoblast cells, reversing H2O2-induced suppression of SIRT1[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; pretreatment following SIRT1 siRNA transfection, followed by 48 h H2O2 exposure) preserves mitochondrial membrane potential in SIRT1-silenced, H2O2-treated MC3T3-E1 preosteoblast cells, indicating its protective effect on mitochondrial function is mediated via SIRT1[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; pretreatment following SIRT1 siRNA transfection, followed by 48 h H2O2 exposure) mitigates oxidative stress in SIRT1-silenced, H2O2-treated MC3T3-E1 preosteoblast cells, indicating its antioxidant effects are mediated via SIRT1[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; pretreatment following SIRT1 siRNA transfection, followed by 48 h H2O2 exposure) enhances autophagy in SIRT1-silenced, H2O2-treated MC3T3-E1 preosteoblast cells, indicating its autophagy-promoting effect is mediated via SIRT1[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-15 μM; pretreatment following SIRT1 siRNA transfection, followed by 48 h H2O2 exposure, then up to 14 days in differentiation medium) restores osteogenic differentiation capacity in SIRT1-silenced, H2O2-treated MC3T3-E1 preosteoblast cells, indicating its pro-osteogenic effect is mediated via SIRT1[3].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (DHPV) (5-20 μM; duration of adipogenesis differentiation) does not reduce viability of 3T3-L1 preadipocytes at concentrations up to 20 μM[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (120 minutes) directly inhibits CDK2/cyclin O kinase activity with an IC50 of 8.79 μM[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (2 mg; overnight at 4°C) directly binds to the CDK2/cyclin O complex in vitro[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (γ-VL) (1-100 μM; 24 h) is non-cytotoxic to primary rat cortical microglia at concentrations from 1 to 50 μM, but induces significant cytotoxicity at 100 μM[6].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (𝛾VL) (1-500 μM; 0-60 min) is subject to calcium2+-dependent hydrolysis catalyzed by pooled male human serum paraoxonase to γ-valeric acid, with an apparent substrate half-life of 9.8 min and a Michaelis-Menten constant (Km) of 269 μM[9].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (1 μM; 1 h) undergoes calcium2+-dependent hydrolysis catalyzed by PON1 and PON3 (but not PON2) expressed in HEK293FT cells to γ-valeric acid, matching activity observed in pooled human serum[9].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (1 μM; 1 h) has specific phase II metabolites that are selectively hydrolyzed by pooled male human serum paraoxonase, with γVL-3'-methoxy-4'-glucuronide, γVL-4'-glucuronide, and γVL-3'-sulfate being the most reactive substrates[9].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (DHPV) (7.5-30 μM; 1 h pretreatment; 5 h TNF-α stimulation) concentration-dependently inhibits TNF-α-stimulated adhesion of THP-1 monocytes to HUVECs, with significant inhibition observed at concentrations as low as 7.5 μM, and does not reduce HUVEC viability at concentrations up to 30 μM[2].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (7.5-30 μM; 1 h pretreatment; 5 h TNF-α stimulation (protein analysis); 4 h TNF-α stimulation (mRNA analysis)) concentration-dependently downregulates TNF-α-stimulated VCAM-1 protein and mRNA expression in HUVECs, with significant suppression observed at concentrations as low as 7.5 μM[2].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (7.5-30 μM; 1 h pretreatment; 5 h TNF-α stimulation (protein secretion analysis); 4 h TNF-α stimulation (mRNA analysis)) concentration-dependently reduces TNF-α-stimulated MCP-1 protein secretion and MCP-1 mRNA expression in HUVECs, with significant suppression observed at concentrations as low as 7.5 μM[2].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (7.5-30 μM; 1 h pretreatment; 10 h TNF-α stimulation) concentration-dependently inhibits TNF-α-stimulated NF-κB transcriptional activation in stably transfected HUVECs, with significant suppression observed at concentrations as low as 7.5 μM[2].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (7.5-30 μM; 1 h pretreatment; 15 min TNF-α stimulation) concentration-dependently suppresses TNF-α-stimulated phosphorylation of IKK and IκBα, and prevents IκBα degradation, in HUVECs, with significant inhibition observed at concentrations as low as 7.5 μM[2].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-20 μM; 6 days) dose-dependently reduces MDI-induced intracellular lipid accumulation in 3T3-L1 preadipocytes, with maximal inhibition at 20 μM reducing lipid content to ~72% of MDI-only control levels[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-20 μM; duration of adipogenesis differentiation) dose-dependently reduces expression of adipogenic (PPAR γ, C/EBP α) and lipogenic (SREBP1c, ACC, FAS) proteins in MDI-induced 3T3-L1 preadipocytes[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5-20 μM; duration of adipogenesis differentiation) dose-dependently reduces MDI-induced phosphorylation of C/EBP β at Thr 188 in 3T3-L1 preadipocytes[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (20 μM; days 0-2 of differentiation) most potently inhibits MDI-induced adipogenesis in 3T3-L1 preadipocytes when applied during the early 0-2 day mitotic clonal expansion stage[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (DHPV) (5-20 μM; 3-4 days) reduces lipid accumulation in mature 3T3-L1 adipocytes by suppressing lipogenic protein expression, without affecting lipolysis[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (20 μM; 16 hours of differentiation) induces G1 phase arrest, delaying MDI-induced cell cycle progression from G1 to S phase in 3T3-L1 preadipocytes[4].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (1-50 μM; 1 h pre-incubation, followed by 24 h LPS stimulation) inhibits LPS-induced release of IL-1β, TNF-α, and NO in primary rat cortical microglia, with significant effects starting at 25 μM for IL-1β and TNF-α, and 50 μM for NO[6].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (1-25 μM in combination with 1-5 μM curcumin; 1 h pre-incubation, followed by 6 or 24 h LPS stimulation) synergizes with Curcumin (HY-N0005) to reduce LPS-induced pro-inflammatory gene expression and mediator release in primary rat cortical microglia, with ZIP model synergy scores ranging from 16.07 to 28.18 for key pro-inflammatory mediators[6].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (5 μM in combination with 5 μM curcumin; 1 h pre-incubation, followed by 6 h LPS stimulation) synergizes with curcumin at 5 μM each to downregulate LPS-induced NLRP3 and NOX2 expression, and upregulate Nrf2 target genes HO-1 and NQO-1, in primary rat cortical microglia[6].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (98 min) demonstrates moderate in vitro antioxidant activity with an ORAC value of 28.8 mmol Trolox/g in the cell-free ORAC assay[7].
5-(3',4'-Dihydroxyphenyl)-γ-valerolactone (10-100 μM) significantly inhibits adherence of UPEC ATCC®53503TM to T24 bladder epithelial cells at 100 μM, with an inhibition rate of 19.4%, and shows no cytotoxicity at concentrations up to 100 μM[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:LS174T human colon adenocarcinoma, HepG2 human hepatocellular carcinoma, Caco2 human colorectal adenocarcinoma, wild type Madin-Darby canine kidney (Wt-MDCK) cells
-
Concentration:1.5 µM, 1.6 µM, 2.5 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM
-
Incubation Time:6 h, 24 h, 48 h
-
Result:Showed no significant reduction in cell viability across all tested concentrations and incubation times.
Maintained >90% cell viability after 6 h exposure.
Left cell viability unaffected up to 48 h.
-
Cell Line:human umbilical vein endothelial cells (HUVECs)
-
Concentration:7.5 μM; 15 μM; 30 μM
-
Incubation Time:1 h pretreatment; 15 min TNF-α stimulation
-
Result:Downregulated TNF-α-stimulated phosphorylation of IKK and IκBα in a concentration-dependent manner, and prevented TNF-α-induced degradation of IκBα.
Reduced relative p-IKK/IKKα/β protein expression to ~7-fold of the control at 7.5 μM, ~5-fold of the control at 15 μM, and ~1-fold of the control at 30 μM.
-
Cell Line:MC3T3-E1 preosteoblast cells
-
Concentration:5-100 μM (direct treatment); 5-15 μM (pretreatment)
-
Incubation Time:24-48 h (direct treatment); 36 h pretreatment, followed by 48 h H2O2 exposure
-
Result:Promoted MC3T3-E1 cell proliferation significantly at 5-15 μM for 36 h.
Suppressed MC3T3-E1 cell proliferation at 50-100 μM.
Ameliorated ~20% cell death induced by 300 μM H2O2 significantly with 5 and 15 μM pretreatment, reducing H2O2-induced cytotoxicity.
-
Cell Line:MC3T3-E1 preosteoblast cells
-
Concentration:5-15 μM
-
Incubation Time:36 h pretreatment, followed by 48 h H2O2 exposure, then up to 14 days in differentiation medium
-
Result:Reversed H2O2-induced downregulation of ALP and Runx2 protein expression significantly.
Restored H2O2-reduced ALP activity significantly.
Increased H2O2-decreased ALP and alizarin red staining intensity significantly.
-
Cell Line:MC3T3-E1 preosteoblast cells
-
Concentration:5-15 μM
-
Incubation Time:36 h pretreatment, followed by 48 h H2O2 exposure
-
Result:Increased H2O2-upregulated LC3-II/I and Beclin-1 expression significantly at 5 μM.
Caused a greater significant increase in H2O2-upregulated LC3-II/I and Beclin-1 expression at 15 μM.
-
Cell Line:MC3T3-E1 preosteoblast cells
-
Concentration:5-15 μM
-
Incubation Time:36 h pretreatment, followed by 48 h H2O2 exposure
-
Result:Showed a non-significant increasing trend in H2O2-reduced SIRT1 protein expression at 5 μM.
Upregulated H2O2-reduced SIRT1 protein expression significantly at 15 μM.
-
Cell Line:SIRT1-silenced MC3T3-E1 preosteoblast cells
-
Concentration:5-15 μM
-
Incubation Time:pretreatment following SIRT1 siRNA transfection, followed by 48 h H2O2 exposure
-
Result:Increased LC3-II/I and Beclin-1 expression decreased by SIRT1 siRNA transfection in H2O2-treated cells significantly, to levels comparable to non-silenced, H2O2-treated cells pretreated with the reagent.
-
Cell Line:SIRT1-silenced MC3T3-E1 preosteoblast cells
-
Concentration:5-15 μM
-
Incubation Time:pretreatment following SIRT1 siRNA transfection, followed by 48 h H2O2 exposure, then up to 14 days in differentiation medium
-
Result:Restored ALP and Runx2 protein expression downregulated by SIRT1 siRNA transfection in H2O2-treated cells significantly.
Restored ALP activity reduced by SIRT1 siRNA transfection in H2O2-treated cells significantly.
Increased ALP and alizarin red staining intensity decreased by SIRT1 siRNA transfection in H2O2-treated cells significantly.
-
Cell Line:3T3-L1 preadipocytes
-
Concentration:20 μM (6 days); 5-80 μM (adipogenesis differentiation)
-
Incubation Time:6 days (20 μM); duration of adipogenesis differentiation (5-80 μM)
-
Result:Did not reduce cell viability at 20 μM when tested alongside other procyanidins and their metabolites.
Remained at ~90-100% of control levels at concentrations up to 20 μM during adipogenesis differentiation.
Reduced viability only at 40 μM and above.
-
Cell Line:MDI-induced 3T3-L1 preadipocytes
-
Concentration:5-20 μM
-
Incubation Time:duration of adipogenesis differentiation
-
Result:Dose-dependently suppressed protein expression of key adipogenic regulators PPAR γ and C/EBP α, as well as lipogenic proteins SREBP1c, acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS).
Showed maximal inhibition observed at 20 μM.\nDose-dependently reduced the phosphorylation of C/EBP β at Thr 188.
Showed maximal reduction observed at 20 μM.
-
Cell Line:MDI-induced 3T3-L1 preadipocytes
-
Concentration:20 μM
-
Incubation Time:0, 8, 16, 20, 24, or 48 hours of differentiation
-
Result:Caused cells treated with both MDI and DHPV to remain arrested in the G1 phase at 16 hours, matching the undifferentiated control group, while MDI-treated cells progressed to the S phase.
Chemical Information
-
CAS No. 21618-92-8
-
Appearance Solid
-
Molecular Weight 208.21
-
Formula C11H12O4
-
Color Off-white to gray
-
SMILES
C1CC(=O)OC1CC2=CC(=C(C=C2)O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Microbiome Analysis
Microbiome analysis characterizes microbial communities in biological or environmental samples by measuring community composition, diversity, taxonomic structure, functional potential, and associations with host or environmental phenotypes. 16S rRNA gene amplicon sequencing is commonly used for bacterial and archaeal taxonomic profiling, while shotgun metagenomics provides higher taxonomic resolution and direct functional information, including microbial genes, pathways, viruses, fungi, and antimicrobial-resistance genes when sequencing depth and host-DNA contamination are adequately controlled. Microbiome results are strongly affected by sample collection, storage, DNA extraction, contamination, sequencing method, reference database, and bioinformatic pipeline; therefore, standardized protocols, negative controls, mock communities, and transparent analysis workflows are required. Unresolved issues include low-biomass contamination, compositional-data bias, inconsistent species-level c
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
Purity & Documentation
-
Data Sheet (300 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Della Vedova L, et al. Pre-ADMET studies of 5-(3',4'-dihydroxyphenyl)-γ-valerolactone, the bioactive intestinal metabolite of proanthocyanidins. Archiv der Pharmazie. 2025 Jan;358(1):e2400575. [Content Brief]
[2]. Lee CC, et al. 5-(3',4'-Dihydroxyphenyl-γ-valerolactone), a Major Microbial Metabolite of Proanthocyanidin, Attenuates THP-1 Monocyte-Endothelial Adhesion. International journal of molecular sciences. 2017 Jun 26;18(7):1363. [Content Brief]
[3]. Chen F, et al. 5-(3',4'-dihydroxyphenyl)-γ-valerolactone, a microbiota metabolite of flavan-3-ols, activates SIRT1-mediated autophagy to attenuate H₂O₂-induced inhibition of osteoblast differentiation in MC3T3-E1 cells. Free radical biology & medicine. 2023 Nov 01;208:309-318. [Content Brief]
[4]. Lee Y, et al. 5-(3',4'-Dihydroxyphenyl)-γ-valerolactone, a metabolite of procyanidins in cacao, suppresses MDI-induced adipogenesis by regulating cell cycle progression through direct inhibition of CDK2/cyclin O. Food Funct. 2019 May 22;10(5):2958-2969. [Content Brief]
[5]. Unno T, et al. Urinary excretion of 5-(3',4'-dihydroxyphenyl)-gamma-valerolactone, a ring-fission metabolite of (-)-epicatechin, in rats and its in vitro antioxidant activity. Journal of agricultural and food chemistry. 2003 Nov 05;51(23):6893-8. [Content Brief]
[6]. Marcolin E, et al. A Combination of 5-(3',4'-Dihydroxyphenyl)-γ-Valerolactone and Curcumin Synergistically Reduces Neuroinflammation in Cortical Microglia by Targeting the NLRP3 Inflammasome and the NOX2/Nrf2 Signaling Pathway. Nutrients. 2025 Apr 10;17(8):1316. [Content Brief]
[7]. Sanchez-Patan F, et al. Synthesis, analytical features, and biological relevance of 5-(3',4'-dihydroxyphenyl)-γ-valerolactone, a microbial metabolite derived from the catabolism of dietary flavan-3-ols. Journal of agricultural and food chemistry. 2011 Jul 13;59(13):7083-91. [Content Brief]
[9]. Momma TY, et al. 5-(3',4'-Dihydroxyphenyl)-γ-Valerolactone Is a Substrate for Human Paraoxonase: A Novel Pathway in Flavan-3-ol Metabolism. Molecular nutrition & food research. 2023 Sep;67(17):e2300281. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)